Selected research
Market Structure
Global Retinoic Acid Receptor Gamma Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Retinoic Acid Receptor Gamma market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Retinoic Acid Receptor Gamma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Retinoic Acid Receptor Gamma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Retinoic Acid Receptor Gamma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Retinoic Acid Receptor Gamma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Retinoic Acid Receptor Gamma include Valeant Pharmaceuticals International Inc, Sol-Gel Technologies Ltd, Promius Pharma LLC, Phosphagenics Ltd, Lee's Pharmaceutical Holdings Ltd, Galderma SA, Clementia Pharmaceuticals Inc, Boehringer Ingelheim GmbH and 3SBio Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Retinoic Acid Receptor Gamma market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Retinoic Acid Receptor Gamma and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Retinoic Acid Receptor Gamma sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Retinoic Acid Receptor Gamma market size, projected growth trends, production technologies, key applications, and end-use industries.
Retinoic Acid Receptor Gamma Segment by Company
Valeant Pharmaceuticals International Inc
Sol-Gel Technologies Ltd
Promius Pharma LLC
Phosphagenics Ltd
Lee's Pharmaceutical Holdings Ltd
Galderma SA
Clementia Pharmaceuticals Inc
Boehringer Ingelheim GmbH
3SBio Inc
Retinoic Acid Receptor Gamma Segment by Type
Tretinoin
Palovarotene
Bexarotene
Alitretinoin
Others
Retinoic Acid Receptor Gamma Segment by Application
Musculoskeletal Disorder
Immunology
Dernatology
Ophthalmology
Others
Retinoic Acid Receptor Gamma Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Retinoic Acid Receptor Gamma market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Retinoic Acid Receptor Gamma and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Retinoic Acid Receptor Gamma.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Retinoic Acid Receptor Gamma market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Retinoic Acid Receptor Gamma manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Retinoic Acid Receptor Gamma in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Retinoic Acid Receptor Gamma in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Tretinoin
- Palovarotene
- Bexarotene
- Alitretinoin
- Others
Applications
- Musculoskeletal Disorder
- Immunology
- Dernatology
- Ophthalmology
- Others
Companies covered
- Valeant Pharmaceuticals International Inc
- Sol-Gel Technologies Ltd
- Promius Pharma LLC
- Phosphagenics Ltd
- Lee's Pharmaceutical Holdings Ltd
- Galderma SA
- Clementia Pharmaceuticals Inc
- Boehringer Ingelheim GmbH
- 3SBio Inc
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Retinoic Acid Receptor Gamma Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Retinoic Acid Receptor Gamma Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Retinoic Acid Receptor Gamma Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Retinoic Acid Receptor Gamma Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Retinoic Acid Receptor Gamma Market Dynamics
- 2.1 Retinoic Acid Receptor Gamma Industry Trends
- 2.2 Retinoic Acid Receptor Gamma Industry Drivers
- 2.3 Retinoic Acid Receptor Gamma Industry Opportunities and Challenges
- 2.4 Retinoic Acid Receptor Gamma Industry Restraints
3 Retinoic Acid Receptor Gamma Market by Manufacturers
- 3.1 Global Retinoic Acid Receptor Gamma Revenue by Manufacturers (2021-2026)
- 3.2 Global Retinoic Acid Receptor Gamma Sales by Manufacturers (2021-2026)
- 3.3 Global Retinoic Acid Receptor Gamma Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Retinoic Acid Receptor Gamma Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Retinoic Acid Receptor Gamma Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Retinoic Acid Receptor Gamma Manufacturers, Product Type & Application
- 3.7 Global Retinoic Acid Receptor Gamma Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Retinoic Acid Receptor Gamma Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Retinoic Acid Receptor Gamma Players Market Share by Revenue in 2025
- 3.8.3 2025 Retinoic Acid Receptor Gamma Tier 1, Tier 2, and Tier 3
4 Retinoic Acid Receptor Gamma Market by Type
- 4.1 Retinoic Acid Receptor Gamma Type Introduction
- 4.1.1 Tretinoin
- 4.1.2 Palovarotene
- 4.1.3 Bexarotene
- 4.1.4 Alitretinoin
- 4.1.5 Others
- 4.2 Global Retinoic Acid Receptor Gamma Sales by Type
- 4.2.1 Global Retinoic Acid Receptor Gamma Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Retinoic Acid Receptor Gamma Sales by Type (2021-2032)
- 4.2.3 Global Retinoic Acid Receptor Gamma Sales Market Share by Type (2021-2032)
- 4.3 Global Retinoic Acid Receptor Gamma Revenue by Type
- 4.3.1 Global Retinoic Acid Receptor Gamma Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Retinoic Acid Receptor Gamma Revenue by Type (2021-2032)
- 4.3.3 Global Retinoic Acid Receptor Gamma Revenue Market Share by Type (2021-2032)
5 Retinoic Acid Receptor Gamma Market by Application
- 5.1 Retinoic Acid Receptor Gamma Application Introduction
- 5.1.1 Musculoskeletal Disorder
- 5.1.2 Immunology
- 5.1.3 Dernatology
- 5.1.4 Ophthalmology
- 5.1.5 Others
- 5.2 Global Retinoic Acid Receptor Gamma Sales by Application
- 5.2.1 Global Retinoic Acid Receptor Gamma Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Retinoic Acid Receptor Gamma Sales by Application (2021-2032)
- 5.2.3 Global Retinoic Acid Receptor Gamma Sales Market Share by Application (2021-2032)
- 5.3 Global Retinoic Acid Receptor Gamma Revenue by Application
- 5.3.1 Global Retinoic Acid Receptor Gamma Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Retinoic Acid Receptor Gamma Revenue by Application (2021-2032)
- 5.3.3 Global Retinoic Acid Receptor Gamma Revenue Market Share by Application (2021-2032)
6 Global Retinoic Acid Receptor Gamma Sales by Region
- 6.1 Global Retinoic Acid Receptor Gamma Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Retinoic Acid Receptor Gamma Sales by Region (2021-2032)
- 6.2.1 Global Retinoic Acid Receptor Gamma Sales by Region (2021-2026)
- 6.2.2 Global Retinoic Acid Receptor Gamma Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Retinoic Acid Receptor Gamma Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Retinoic Acid Receptor Gamma Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Retinoic Acid Receptor Gamma Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Retinoic Acid Receptor Gamma Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Retinoic Acid Receptor Gamma Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Retinoic Acid Receptor Gamma Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Retinoic Acid Receptor Gamma Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Retinoic Acid Receptor Gamma Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Retinoic Acid Receptor Gamma Revenue by Region
- 7.1 Global Retinoic Acid Receptor Gamma Revenue by Region
- 7.1.1 Global Retinoic Acid Receptor Gamma Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Retinoic Acid Receptor Gamma Revenue by Region (2021-2026)
- 7.1.3 Global Retinoic Acid Receptor Gamma Revenue by Region (2027-2032)
- 7.1.4 Global Retinoic Acid Receptor Gamma Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Retinoic Acid Receptor Gamma Revenue (2021-2032)
- 7.2.2 North America Retinoic Acid Receptor Gamma Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Retinoic Acid Receptor Gamma Revenue (2021-2032)
- 7.3.2 Europe Retinoic Acid Receptor Gamma Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Retinoic Acid Receptor Gamma Revenue (2021-2032)
- 7.4.2 Asia-Pacific Retinoic Acid Receptor Gamma Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Retinoic Acid Receptor Gamma Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Retinoic Acid Receptor Gamma Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Valeant Pharmaceuticals International Inc
- 8.1.1 Valeant Pharmaceuticals International Inc Company Information
- 8.1.2 Valeant Pharmaceuticals International Inc Business Overview
- 8.1.3 Valeant Pharmaceuticals International Inc Retinoic Acid Receptor Gamma Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Valeant Pharmaceuticals International Inc Retinoic Acid Receptor Gamma Product Portfolio
- 8.1.5 Valeant Pharmaceuticals International Inc Recent Developments
- 8.2 Sol-Gel Technologies Ltd
- 8.2.1 Sol-Gel Technologies Ltd Company Information
- 8.2.2 Sol-Gel Technologies Ltd Business Overview
- 8.2.3 Sol-Gel Technologies Ltd Retinoic Acid Receptor Gamma Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Sol-Gel Technologies Ltd Retinoic Acid Receptor Gamma Product Portfolio
- 8.2.5 Sol-Gel Technologies Ltd Recent Developments
- 8.3 Promius Pharma LLC
- 8.3.1 Promius Pharma LLC Company Information
- 8.3.2 Promius Pharma LLC Business Overview
- 8.3.3 Promius Pharma LLC Retinoic Acid Receptor Gamma Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Promius Pharma LLC Retinoic Acid Receptor Gamma Product Portfolio
- 8.3.5 Promius Pharma LLC Recent Developments
- 8.4 Phosphagenics Ltd
- 8.4.1 Phosphagenics Ltd Company Information
- 8.4.2 Phosphagenics Ltd Business Overview
- 8.4.3 Phosphagenics Ltd Retinoic Acid Receptor Gamma Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Phosphagenics Ltd Retinoic Acid Receptor Gamma Product Portfolio
- 8.4.5 Phosphagenics Ltd Recent Developments
- 8.5 Lee's Pharmaceutical Holdings Ltd
- 8.5.1 Lee's Pharmaceutical Holdings Ltd Company Information
- 8.5.2 Lee's Pharmaceutical Holdings Ltd Business Overview
- 8.5.3 Lee's Pharmaceutical Holdings Ltd Retinoic Acid Receptor Gamma Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Lee's Pharmaceutical Holdings Ltd Retinoic Acid Receptor Gamma Product Portfolio
- 8.5.5 Lee's Pharmaceutical Holdings Ltd Recent Developments
- 8.6 Galderma SA
- 8.6.1 Galderma SA Company Information
- 8.6.2 Galderma SA Business Overview
- 8.6.3 Galderma SA Retinoic Acid Receptor Gamma Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Galderma SA Retinoic Acid Receptor Gamma Product Portfolio
- 8.6.5 Galderma SA Recent Developments
- 8.7 Clementia Pharmaceuticals Inc
- 8.7.1 Clementia Pharmaceuticals Inc Company Information
- 8.7.2 Clementia Pharmaceuticals Inc Business Overview
- 8.7.3 Clementia Pharmaceuticals Inc Retinoic Acid Receptor Gamma Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Clementia Pharmaceuticals Inc Retinoic Acid Receptor Gamma Product Portfolio
- 8.7.5 Clementia Pharmaceuticals Inc Recent Developments
- 8.8 Boehringer Ingelheim GmbH
- 8.8.1 Boehringer Ingelheim GmbH Company Information
- 8.8.2 Boehringer Ingelheim GmbH Business Overview
- 8.8.3 Boehringer Ingelheim GmbH Retinoic Acid Receptor Gamma Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Boehringer Ingelheim GmbH Retinoic Acid Receptor Gamma Product Portfolio
- 8.8.5 Boehringer Ingelheim GmbH Recent Developments
- 8.9 3SBio Inc
- 8.9.1 3SBio Inc Company Information
- 8.9.2 3SBio Inc Business Overview
- 8.9.3 3SBio Inc Retinoic Acid Receptor Gamma Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 3SBio Inc Retinoic Acid Receptor Gamma Product Portfolio
- 8.9.5 3SBio Inc Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Retinoic Acid Receptor Gamma Value Chain Analysis
- 9.1.1 Retinoic Acid Receptor Gamma Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Retinoic Acid Receptor Gamma Production Mode & Process
- 9.2 Retinoic Acid Receptor Gamma Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Retinoic Acid Receptor Gamma Distributors
- 9.2.3 Retinoic Acid Receptor Gamma Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst